SOLAEROMED ANNOUNCES POSITIVE PROOF OF CONCEPT DATA FOR ITS LEAD DRUG (S-1226) IN SUBJECTS WITH MILD ATOPIC ASTHMA
Calgary, Alberta – SolAeroMed Inc., a Calgary-based biotechnology company dedicated to developing novel drugs and devices to treat respiratory diseases, announced positive Phase IIa proof-of-concept results for its S-1226 lead therapeutic. The Phase IIa study was a placebo-controlled, randomized, double-blind, crossover single dose study to evaluate the safety, tolerability and efficacy of S-1226 (8%) administered by nebulization in subjects with mild atopic asthma.
“We are delighted to have achieved clinical proof of concept for S-1226....